Stryker Corporation $SYK Shares Acquired by Dundas Partners LLP

Dundas Partners LLP lifted its position in shares of Stryker Corporation (NYSE:SYK) by 9.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 98,694 shares of the medical technology company’s stock after purchasing an additional 8,172 shares during the period. Stryker comprises approximately 2.6% of Dundas Partners LLP’s portfolio, making the stock its 19th largest position. Dundas Partners LLP’s holdings in Stryker were worth $36,484,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the business. Brighton Jones LLC lifted its holdings in Stryker by 15.4% during the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock worth $1,643,000 after buying an additional 609 shares during the last quarter. Schnieders Capital Management LLC. purchased a new position in shares of Stryker in the 2nd quarter valued at about $205,000. Vestmark Advisory Solutions Inc. increased its holdings in shares of Stryker by 73.4% in the 2nd quarter. Vestmark Advisory Solutions Inc. now owns 7,463 shares of the medical technology company’s stock valued at $2,953,000 after acquiring an additional 3,159 shares during the last quarter. KCM Investment Advisors LLC raised its position in shares of Stryker by 1.9% during the 2nd quarter. KCM Investment Advisors LLC now owns 1,925 shares of the medical technology company’s stock worth $762,000 after acquiring an additional 35 shares in the last quarter. Finally, AE Wealth Management LLC lifted its stake in Stryker by 31.1% during the second quarter. AE Wealth Management LLC now owns 3,037 shares of the medical technology company’s stock worth $1,202,000 after purchasing an additional 720 shares during the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Insider Buying and Selling at Stryker

In related news, Director Ronda E. Stryker sold 250,000 shares of the firm’s stock in a transaction dated Wednesday, February 4th. The stock was sold at an average price of $362.92, for a total transaction of $90,730,000.00. Following the transaction, the director owned 2,457,331 shares of the company’s stock, valued at $891,814,566.52. This trade represents a 9.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Company insiders own 5.20% of the company’s stock.

Stryker Stock Performance

Shares of SYK opened at $364.11 on Monday. The company’s 50 day simple moving average is $365.45 and its 200-day simple moving average is $368.84. The firm has a market cap of $139.34 billion, a PE ratio of 43.35, a price-to-earnings-growth ratio of 2.13 and a beta of 0.85. Stryker Corporation has a 12-month low of $329.16 and a 12-month high of $404.87. The company has a current ratio of 1.89, a quick ratio of 1.21 and a debt-to-equity ratio of 0.66.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, January 29th. The medical technology company reported $4.47 EPS for the quarter, beating the consensus estimate of $4.40 by $0.07. The firm had revenue of $7.17 billion during the quarter, compared to the consensus estimate of $7.12 billion. Stryker had a net margin of 12.92% and a return on equity of 24.41%. Stryker’s revenue for the quarter was up 11.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $4.01 EPS. As a group, equities analysts predict that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st will be paid a dividend of $0.88 per share. The ex-dividend date is Tuesday, March 31st. This represents a $3.52 annualized dividend and a dividend yield of 1.0%. Stryker’s dividend payout ratio is 41.90%.

Analysts Set New Price Targets

Several brokerages have commented on SYK. Sanford C. Bernstein increased their price target on shares of Stryker from $450.00 to $465.00 and gave the company an “outperform” rating in a research note on Friday, January 9th. Robert W. Baird set a $437.00 target price on shares of Stryker in a report on Friday, January 30th. William Blair reiterated an “outperform” rating on shares of Stryker in a research note on Thursday. Weiss Ratings reissued a “hold (c+)” rating on shares of Stryker in a research report on Monday, December 22nd. Finally, Piper Sandler reaffirmed an “overweight” rating on shares of Stryker in a report on Tuesday, January 27th. Fourteen research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $428.61.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.